The circadian variation in urinary leukotriene E 4 (LTE 4 ) excretion with a morning acrophase has recently been reported in nocturnal asthma (NA); however, the effects of inhaled corticosteroids (ICS) on this circadian rhythmicity of leukotriene (LT) in patients with NA are controversial. Methods: We first measured peak expiratory flow (PEF), urinary LTE 4 , 11-dehydro-thromboxane B 2 (TXB 2 ), and creatinine levels six times every 4 h for 24 h in two groups: patients with mild-to-moderate, steroid-naive NA (n ‫؍‬ 10, group A), and patients with severe NA treated with high-dose ICS (n ‫؍‬ 10, group B). Next, group A patients received 2 weeks of treatment with 800 g/d of inhaled fluticasone propionate (FP), and we compared the measured parameters before and after treatment. Results: In group A, a circadian rhythm in urinary LTE 4 with peak levels at approximately 4 AM associated with reduced PEF was observed. Group B had suppression of urinary LTE 4 excretion and had no circadian rhythmicity, as seen in group A, despite a dip in PEF at 4 AM. A high dose of FP in group A significantly (p < 0.05) reduced LTE 4 levels and abolished the circadian rhythm, as well as improving PEF. We found no significant difference in the circadian rhythm of urinary 11-dehydro-TXB 2 between groups A and B, and high-dose FP partially decreased urinary 11-dehydro-TXB 2 levels but not significantly. Conclusions: A high-dose of ICS reduced urinary LTE 4 levels and abolished their circadian variation in patients with asthma, suggesting that LT might contribute to the mechanism of NA.
C
ysteinyl-leukotrienes (LTs) and thromboxane A 2 are metabolites of arachidonic acid with a bronchoconstrictive potency that is Ͼ 1,000 times that of histamine. 1, 2 Urinary leukotriene E 4 (LTE 4 ) excretion rates increase during severe asthma attacks, 3 and decrease during 5-lipoxygenase inhibitor treatment. 4 Urinary 11-dehydro-thromboxane B 2 (TXB 2 ) excretion also increases during severe asthmatic exacerbations and decreases after aspirin intake. 5, 6 Measurement of these urinary stable metabolites (LTE 4 and TXB 2 ) may be useful markers for evaluating asthmatic status.
Nocturnal exacerbations are common in asthmatics, but the role of LTs in nocturnal asthma (NA) remains controversial. 7, 8 Asano et al 9 reported that asthmatic patients excrete LTE 4 in the urine at a greater rate than normal subjects, but found no systematic variation in urinary LTE 4 excretion rates over the course of a day in either normal or asthmatic subjects. In contrast, Bellia et al 10 reported that urinary LT excretion at night was significantly higher in patients with NA than in healthy subjects or nonnocturnal asthmatics, and a significant linear correlation existed between the morning dip in peak expiratory flow (PEF) and urinary LTE 4 levels. We found a circadian rhythmicity of urinary LTE 4 with a morning acrophase in patients with NA, but not in nonnocturnal asthmatic subjects. 11 NA is associated with a significant increase of eosinophils in BAL fluid, and of eosinophils and macrophages in the alveolar tissue sampled at 4 am. 12, 13 These inflammatory cells are known to produce LTs and thromboxane (TX). Inhaled corticosteroids (ICS) are the first line of anti-inflammatory treatment for asthma, but whether they reduce LT synthesis in vivo remains controversial. Several studies 14 -16 suggest that inhaled or oral steroids do not change urinary LTE 4 levels either in healthy people or in patients with mild asthma; however, IV administration of corticosteroids inhibited leukotriene production in acute asthma, while inhaled fluticasone propionate (FP) [500 g/d for 4 weeks] significantly decreased sputum leukotriene B 4 (LTB 4 ) levels in severe bronchiectasis. 17, 18 Our aims were to determine whether high-dose therapy with ICS alters the circadian rhythm of LT and TX in patients with NA, and to examine the contribution of arachidonic acid metabolites to the pathogenesis of NA.
Materials and Methods

Study Population
All subjects were recruited from Sapporo Medical University Hospital. Twenty patients with NA (8 men and 12 women) were chosen at random from a larger group of non-aspirin-sensitive asthmatics (Table 1) . We defined asthma using the American Thoracic Society criteria with a documented daytime improvement in percentage of predicted FEV 1 of Ն 15% after ␤ 2 -agonist inhalation. 19 NA was defined as a documented fall in the overnight PEF of Ն 15% and asthma symptoms in the early morning on at least 8 nights in the 2-week period preceding the study. 20 Patients were excluded if they had had other acute respiratory illnesses or had had a moderate-to-severe asthma exacerbation within 1 month before the study. All had normal renal function, and had not had symptoms of gastroesophageal reflux and excess obesity, which cause sleep disturbance. Only people with a Ն 2 ϩ reaction to antigen-specific serum IgE of 23 common antigens as tested by a commercial kit (CAP RAST system; Pharmacia Diagnostics; Uppsala, Sweden) were considered for atopy. There were 10 asthmatic patients not receiving ICS therapy (group A) and 10 patients receiving ICS (group B). Asthma severity was classified according to published guidelines. 21 Severe asthma is defined as having continuous symptoms with FEV 1 Ͻ 60% predicted before asthma treatment, and high-dose inhaled steroid therapy (beclomethasone dipropionate [BDP] , Ͼ 800g/d) needs for best possible results. Moderate asthma is defined as daily symptoms with FEV 1 Ͼ 60% and Ͻ 80% predicted before treatment. Mild asthma is defined as FEV 1 Ͼ 80% predicted before treatment. In group A, five patients had mild asthma and another five patients had moderate asthma, while all patients in group B had severe asthma. Patient characteristics are summarized in Table 1 . All subjects gave written informed consent to participate in this study.
Study Design
All subjects were admitted to Sapporo Medical University Hospital during this study. Theophylline and inhaled ␤ 2 -agonists were discontinued 24 h before the study began, and patients refrained from exercise and rested during the 24 h of the study. Urine collection for determination of creatinine, LTE 4, and 11-dehydro-TXB 2 began at noon on the first study day, and was performed every 4 h (4 pm, 8 pm, midnight, 4 am, 8 am, and noon) along with PEF measurements. Each patient received instruction on PEF measurements using a Mini-Wright Peak Flowmeter (Clement Clarke International; Harlow, Essex, UK). To confirm the effects of short-term ICS, we approached all group A patients about an additional 2-week treatment with FP and re-examination by 24-h monitoring of PEF, urinary LTE 4 , and 11-dehydro TXB 2 excretion. Seven of 10 patients in group A agreed to the second study and received inhaled FP dry powder (800 g/d for 2 weeks). We compared measurements before and after this treatment.
Measurement of Urinary LTE 4
Each patient provided approximately 30 mL of urine in a polypropylene container. Immediately after collection, 4 mL of solution (ethyl acetate: methanol, 2:1) was added to each 1 mL of urine specimen to eliminate proteins; the specimens were then frozen at -70°C until assayed for urinary creatinine and LTE 4 . We have reported previously our assay method. 22 Using a reverse-phase, high-pressure liquid chromatography gradient system equipped with a Nova-Pak C18 column (Waters Associates; Milford, MA), LTE 4 was measured with a Leukotriene [ 3 H] Radioimmunoassay Kit (DuPont New England Nuclear Research; Boston, MA). Measurements were corrected according to the creatinine content of urine, and levels were expressed as picograms per milligram of creatinine. The recovery rate of tritiated LTE 4 was from 50 to 60%. The intra-assay and interassay coefficients of variation were 11% and 10%, respectively.
Measurement of Urinary 11-dehydro-TXB 2
Indomethacin was added to the urine samples, which were stored at -70°C. We have previously reported our method of measuring of urinary 11-dehydro-TXB 2 . 22 After deproteinization and defatting, the samples were applied to a Si minicolumn BOND ELUT SI (Varian; Harbor City, CA) and subsequently fractionated by eluent 1 (chloroform:acetic acid, 100:0.5), eluent 2 (acetonitrile:chloroform: acetic acid, 10:90:0.5), and eluent 3 (acetonitrile:chloroform:acetic acid, 20:80:0.5). The fraction obtained by eluent 3 was evaporated using N 2 gas and reconstituted with the buffer of the 11-dehydro-thromboxane B 2 [
125 I] Radioimmunoassay Kit (DuPont New England Nuclear Research). 11-dehydro-TXB 2 was measured using this kit, and the recovery rate of tritiated 11-dehydro-TXB 2 was 61.5%.
Statistical Analysis
Results were expressed as mean Ϯ SE.
2 test and MannWhitney U test were used for analysis of patients' backgrounds, and the Mann-Whitney U test was used to compare mean values of PEF, and levels of urinary LTE 4 and 11-dehydro-TXB 2 between groups A and B. In the second study, for comparisons of PEF, LTE 4 , and 11-dehydro-TXB 2 levels before and after ICS therapy and between two different clock times, we employed the Wilcoxon signed-rank test; p Ͻ 0.05 was considered statistically significant.
Results
Using values from the patients' asthma diaries, PEF before and during the study was not different. No patients needed rescue medications during the study. Subjects' characteristics and pulmonary function test results are shown in Table 1 . Group A patients had significantly higher (p Ͻ 0.01) peripheral blood eosinophils than those in group B. There were no significant differences in pulmonary function. Eleven patients were nonatopic and 9 patients were atopic in groups A and B. The mean value of PEF in atopic asthmatics did not differ from that in nonatopic asthmatics. The mean levels of urinary LTE 4 and 11-dehydro-TXB 2 levels of the six measurements were not significantly different between atopic and nonatopic patients.
In the first study, the mean value and circadian rhythmicity of PEF was not different between groups A and B (Fig 1, top; Table 2 ). Mean urinary LTE 4 levels in group A were significantly (p Ͻ 0.05) higher in the midnight to 4 am and 4 am to 8 am time periods as compared with group B (Fig 1,  middle) , and circadian rhythmicity with a morning acrophase was detected in group A but not in group B (Table 2) . Urinary 11-dehydro-TXB 2 levels in each time period were not different between groups A and B (Fig 1, bottom) . Group A exhibited circadian Figure 1 . Comparisons of PEF (top), urinary LTE 4 (middle), and 11-dehydro-TXB 2 (bottom) between patients with steroidnaive, mild-to-moderate NA (group A) and patients with severe NA receiving high-dose ICS (group B). Although the morning dip in PEF is similar between groups A and B, urinary LTE 4 levels are elevated only in group A. There is no difference in urinary 11-dehydro-TXB 2 between the groups. variation with a morning acrophase, but this was not seen in group B (Table 2 ).
In the second study, asthma symptoms in the early morning disappeared and PEF levels at 8 pm, midnight, 4 am, and 8 am were significantly (p Ͻ 0.05) improved after high-dose FP therapy (Fig 2, top) . The mean PEF value in group A at 4 am after ICS therapy was significantly (p Ͻ 0.05) higher than before FP therapy (Table 3) , and the morning dip was abolished (Fig 2, top) . The mean levels of LTE 4 in the 4 to 8 pm, 8 pm to midnight, midnight to 4 am, 4 to 8 am time periods were significantly (p Ͻ 0.05) decreased by 2 weeks of FP therapy in steroid-naive asthmatic patients (Fig 2, middle) . Furthermore, the circadian rhythmicity was lost after this therapy (Table 3 ). There were no significant differences between before and after FP therapy in the levels of urinary 11-dehydro-TXB 2 (Fig 2, bottom; Table 3 ).
Discussion
We recently observed the existence of circadian rhythm of urinary LTE 4 with a morning peak in steroid-naive NA but not in steroid-naive non-NA. 11 Although we changed sampling method from every 3 h to every 4 h in the present study, the same circadian rhythm was found in steroid-naive NA. LTE 4 appeared in urine within the first 1 to 4 h after IV infusion of cysteinyl-LTs 23 ; therefore, a 4-h urine sample would reflect the detail changes of LTs that occurred over the 4 h prior to sampling, suggesting that morning dip of PEF at approximately 4 am reflects on urinary LTE 4 levels during 4 to 8 am. In this study, the high dose of FP simultaneously reduced the mean levels of LTE 4 , abolished the circadian rhythm in urinary LTE 4 and PEF, and disappeared asthma symptoms in the early morning in steroid-naive NA. On the contrary, in patients with severe NA who had been treated with high-dose BDP, the urinary LTE 4 excretion was lowered and the circadian rhythm abolished but nocturnal symptoms and a dip of PEF at 4 am remained. It was reported that 14 of 17 patients with severe asthma who received Ͼ 20 mg of prednisolone for Ն 1 year had reduced LTE 4 levels in BAL fluid to the levels of normal control subjects. 24 Jatakanon 25 suggested a potential role of neutrophils rather than eosinophils in more severe asthma because the number of neutrophils, interleukin-8, and myeloperoxidase levels in sputum were high. LTC 4 is mainly produced in epithelial cells, eosinophils, and mast cells. Moreover, cysteinyl LT-1 receptor antagonists are more effective in mild asthma as compared to severe asthma. 26 We suggested that LTs might make a greater contribution to nocturnal exacerbations in patients with mild-to-moderate, steroid-naive asthma than in those treated with high-dose ICS. It was speculated that the morning dip in patients with severe NA with high-dose ICS might occur due to LTs and other bronchoconstrictive factors. This is the first study to investigate the effect of short-term, high-dose ICS on the circadian rhythmicity of LT production in NA. Previous studies of the effects of ICS on LT production were inconclusive. Powell et al 27 suggested that glucocorticoids reduced the biliary levels of cysteinyl-LTs in allergen-induced airway responses in rats, and Tsang et al 18 reported that FP therapy (500 g/d for 4 weeks) significantly reduced serum LTB 4 in severe bronchiectasis. 18, 27 However, Manso et al 15 found that 7 days of therapy with 1,600 g/d of budesonide did not decrease urinary LTE 4 , but this study was probably invalid because the values in the study subjects (healthy subjects) before treatment were already as low as 20 pg/mg creatinine, making any effect of ICS difficult to detect. O'Shaughnessy et al 14 reported no effects of FP (1,000 g/d for 14 days) on urinary LTE 4 excretion 4 h after allergen challenge in mild atopic asthma, while Dworski et al 16 also failed to find any inhibition of LTE 4 in BAL fluid by glucocorticoids in atopic asthma after allergen instillation. In both studies, 14, 16 the effects of steroid on LTE 4 levels in urine or BAL were evaluated by the change after allergen challenge. The differences in pretreatment lower LTE 4 levels (probably due to nonasthmatic healthy subjects) and in method of evaluation (the change a short time after allergen challenge) may explain why previous studies failed to find an ICS inhibitory effect on LT production.
In the present study, a high-dose of ICS had a more suppressive effect on LT production as compared to TX synthesis. These results agree with those of previous studies. 28, 29 Wenzel et al 28 reported that a single dose of prednisolone decreased LTB 4 production, but not 11-dehydro-TXB 2 generation, from pulmonary alveolar macrophages obtained by BAL at 4 am in patients with NA. 28 Nakamura et al 29 reported that the effects of steroid on the production of eicosanoids differed in TX and LTs: steroid therapy slightly lowered urinary 11-dehydro-TXB 2 , but significantly decreased urinary LTE 4 , in patients with rheumatoid arthritis. We also observed that 7 days of methylprednisolone treatment significantly reduced urinary LTE 4 , but only had a trend to decrease urinary 11-dehydro-TXB 2 in asthmatic patients with acute exacerbations (H. Tanaka, MD; unpublished data; May 1998).
We could not determine the mechanism by which ICS suppressed LT production. Hancox et al 30 reported that 6 weeks of treatment with inhaled budesonide (400 g/d) reduced the binding activity of the proinflammatory transcription factor nuclear factor-B (NFkB) in bronchial mucosa in asthmatic subjects, which supports the finding that corticosteroids reduce the level of NFkB binding DNA in human lung tissue and peripheral blood mononuclear cells. 31, 32 Wilson et al 33 also demonstrated that the anti-inflammatory effects of ICS are mediated through inhibition of NFkB-regulated gene expression. Possibly, inhibition by ICS may be both of the following: (1) direct suppression of the activity of LT producing inflammatory cells, and (2) indirect by reducing eosinophils, lymphocytes, and other inflammatory cells from the airway, and down-regulating cytokine and chemokine, which leads to decreased LTs. We conclude that high-dose ICS therapy can reduce urinary LTE 4 levels and abolish urinary LTE 4 circadian rhythmicity in patients with asthma, and that LTs may play an important role in the mechanism of nocturnal exacerbations.
